Highlights

  • Chardan Capital reaffirmed its rating with a USD 14.00 price objective.
  • Analyst views on COYA remain mixed across multiple research firms.
  • Latest quarterly results showed a wider loss versus market expectations.

Coya Therapeutics (NASDAQ:COYA) remains under analyst coverage following a research note from Chardan Capital, which reaffirmed its “buy” rating on the stock, according to a report cited by Benzinga. The brokerage maintained a price target of USD 14.00, referencing its assessment of the company’s clinical-stage portfolio and development outlook.

The reiterated target reflects a substantial gap relative to the stock’s prior closing level, though the research note did not include changes to underlying assumptions. Chardan Capital’s stance follows a series of rating actions from other firms in recent months.

Broader Analyst Coverage

COYA has received varied assessments from several research houses. HC Wainwright previously reiterated a “buy” rating, while BTIG Research increased its price target from USD 15.00 to USD 16.00 and maintained a positive rating. D. Boral Capital also reissued a “buy” rating with a USD 15.00 target.

In contrast, Wall Street Zen adjusted its view upward from “sell” to “hold,” while Weiss Ratings reaffirmed a “sell (d-)” designation earlier in October. Based on available data compiled by MarketBeat.com, five analysts currently classify the stock as “buy,” while one assigns a “sell” rating. The aggregated consensus rating is listed as “Moderate Buy,” with an average price target of USD 16.00.

Recent Financial Performance

Coya Therapeutics last reported quarterly results on November 12. The company posted a loss of USD 0.10 per share, compared with consensus expectations for a USD 0.02 loss, resulting in a wider-than-anticipated shortfall. Quarterly revenue was reported at USD 3.56 million, slightly below analyst estimates of USD 3.70 million.

Financial metrics for the period reflected a negative return on equity of 55.76% and a net margin of minus 462.24%. Analysts currently project a full-year loss of approximately USD 1.15 per share.

Company Overview

Coya Therapeutics is a clinical-stage biotechnology company focused on developing therapies targeting UNC-45A, a molecular chaperone involved in fibrosis and cancer-related pathways. Its pipeline includes COY-001, a preclinical candidate for fibrotic diseases, and COY-002, which is being prepared for clinical evaluation in solid tumors.

COYA closed at USD 5.12 on January 08, 2026.